Abdominal/gastrointestinal complaints are the most prevalent initial symptoms in DLBCL, reported by 26% of patients. Peripheral lymphadenopathy and testicular tumors are associated with low-risk ...

ADC Therapeutics SA (NYSE: ADCT) today announced topline data from its Phase 3 LOTIS-5 confirmatory trial evaluating ...

Higher rates of adverse events offset the positive survival results in an area of great unmet need. For decades, the standard ...

Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.

Recent noteworthy reports on diffuse large B-cell lymphoma (DLBCL) include positive survival results with an antibody-drug conjugate in relapsed/refractory disease, FDA issues with a randomized trial, ...

Add Yahoo as a preferred source to see more of our stories on Google. Few agents define SoC for first-line DLBCL Treatment of refractory or relapsed (R/R) diffuse large B-cell lymphoma (DLBCL) has ...

Add-on tafasitamab and lenalidomide did not negatively impact chemotherapy backbone ...

The addition of two agents to standard first-line treatment significantly improved PFS among patients with aggressive B-cell lymphomas, according to results of the randomized phase 3 frontMIND ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — In this video, Paolo F. Caimi, MD, MBA, staff physician at Cleveland Clinic, discusses the phase 2/3 ...

MicroRNAs are small non-coding RNAs, typically 20–24 nucleotides long, that modulate gene expression post-transcriptionally by binding to complementary sequences in target messenger RNAs. In B-cell ...

B-cell lymphoma is a type of non-Hodgkin lymphoma. It’s also the most common type of lymphoma. Approximately 85% of all lymphomas in the United States are B-cell lymphomas. Non-Hodgkin lymphomas are ...